Grant Details
Grant Number: |
5R01CA077376-04 Interpret this number |
Primary Investigator: |
Haile, Robert |
Organization: |
University Of Southern California |
Project Title: |
DNA Methylation and Colorectal Polyps |
Fiscal Year: |
2003 |
Abstract
DESCRIPTION: (Adapted from the Applicant's Abstract): Our overall objective is
to better define the role DNA methylation in the etiology of colorectal
adenomas, and to assess potential risk factors for de novo methylation in
adenomas. We propose to accomplish our objective by adding a methylation
component onto an existing sigmoidoscopy-based case-control study of
environmental and genetic risk factors for adenomatous polyps of the large
bowel that will have 1,000 cases and 1,000 controls, with food frequency and
risk factors questionnaires, a fasting blood sample, and, for cases, pathology
reports and tumor blocks. We propose the following aims:
First, we will conduct a descriptive study of de novo methylation in five
specific genes, three known tumor suppressor genes (APC, hMLH1, and p16)
involved in colorectal of hypermethylation of the promoter region cancer, the
estrogen receptor (ER), which may or may not be directly involved in the
etiology of colorectal polyps, and a "control" gene, MYOD, that is clearly not
involved in colorectal cancer. Second, we will assess two hypotheses regarding
risk factors for hypermethylation. The first is that decreased dietary or RBC
folic acid will be associated with an increase prevalence of hypermethylation
of the promoter region of the ER. As part of this hypothesis, we will assess
modification of the folic acid-methylation relationship by a gene,
methylene-tetrahydrofolate reductase (MTHFR), that is involved in folic acid
metabolism. The second hypothesis is that use of postmenopausal hormones will
be associated with a lower prevalence of hypermethylation of the ER. Third, we
will determine if there are differences in the methylation status of the five
target genes in adenomas with the replication error phenotype (RER+) compared
to adenomas without that phenotype (RER-). We propose to measure methylation
status with a new procedure (COBRA), developed by Dr. Peter Laird , that more
sensitive and quantitative than other assays that can feasibly be conducted on
a large sampled of paraffin-embedded tissue. Combining this assay with our
ongoing study will provide us with a powerful means of addressing important
questions about methylation and its role on cancer. We propose to measure
methylation status with a new procedure (COBRA), developed by Dr. Peter Laird,
that is more sensitive and quantitative than other assay with our ongoing study
will provide a powerful means of addressing important questions about
methylation and its role on cancer etiology.
Publications
None